



VPI/99-06 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Salituro et al.
Serial No.: 10/008,277
Filing Date: December 3, 2001 (03.12.01)
For: INHIBITORS OF c-JUN N-TERMINAL
KINASES

Cambridge, Massachusetts
April 12, 2002

Hon. Assistant Commissioner
For Patents
Washington, D.C. 20231

Attention: Application Processing Division,
Special Processing and Correspondence Branch

TRANSMITTAL LETTER FOR NOTICE TO FILE CORRECTED
APPLICATION PAPERS

Sir:


Transmitted herewith in response to the Notice
To File Corrected Application Papers - Filing Date
Granted, mailed February 14, 2002, are the following
materials relating to the above-identified application:

1. Transmittal letter for Notice To File
Corrected Application Papers
2. Notice To File Corrected Application
Papers
3. Response to Notice To File Corrected
Application Papers
4. Preliminary Amendment

5. Replacement Specification pages 2-33
6. Sequence Listing & Diskette
7. Verified Statement Under 37 C.F.R.
8. Executed Declaration and Power of Attorney
9. Certificate of Mailing
10. Return Receipt Postcard


Applicant's believe that no additional fees are due at this time however, the Commissioner is hereby authorized to charge payment of additional fees required under 37 C.F.R. § 1.16 in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



Andrea L.C. Robidoux
(Reg.No. 47,902)
Agent for Applicants
C/O Vertex Pharmaceuticals Inc.
130 Waverly Street
Cambridge, MA 02139-4242
Tel: (617) 444-6731
Fax: (617) 444-6483

April 12, 2002
Date



VPI/99-06 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Salituro et al.
Serial No.: 10/008,277
Filing Date: December 3, 2001 (03.12.01)
For: INHIBITORS OF c-JUN N-TERMINAL
KINASES

Cambridge, Massachusetts
April 12, 2002

Hon. Assistant Commissioner
For Patents
Washington, D.C. 20231

Attention: Application Processing Division,
Special Processing and Correspondence Branch


RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Sir:

This is in response to the Notice To File Corrected Application Papers - Filing Date Granted, mailed February 14, 2002 ("the Notice"). The Notice indicates that the application is informal as filed and the following items are required:

- (a) substitute Specification pages 2-33 in compliance with 37 C.F.R. § 1.52; and
- (b) a Sequence Listing pursuant to 37 C.F.R. §§ 1.821-1.825.

Applicants submit herewith the required Sequence Listing and statement pursuant to 37 C.F.R. §§ 1.821-1.825. Applicants also submit a Preliminary



04-15-02

03CO

VPI/99-06 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Salituro et al.
Serial No.: 10/008,277
Filing Date: December 3, 2001 (03.12.01)
For: INHIBITORS OF c-JUN N-TERMINAL
KINASES

Cambridge, Massachusetts
April 12, 2002

Hon. Assistant Commissioner
For Patents
Washington, D.C. 20231

Attention: Application Processing Division,
Special Processing and Correspondence Branch

TRANSMITTAL LETTER FOR NOTICE TO FILE CORRECTED
APPLICATION PAPERS

Sir:


Transmitted herewith in response to the Notice
To File Corrected Application Papers - Filing Date
Granted, mailed February 14, 2002, are the following
materials relating to the above-identified application:

1. Transmittal letter for Notice To File
Corrected Application Papers
2. Notice To File Corrected Application
Papers
3. Response to Notice To File Corrected
Application Papers
4. Preliminary Amendment

5. Replacement Specification pages 2-33
6. Sequence Listing & Diskette
7. Verified Statement Under 37 C.F.R.
8. Executed Declaration and Power of Attorney
9. Certificate of Mailing
10. Return Receipt Postcard

Applicant's believe that no additional fees are due at this time however, the Commissioner is hereby authorized to charge payment of additional fees required under 37 C.F.R. § 1.16 in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



April 12, 2002
Date


Andrea L.C. Robidoux
(Reg.No. 47,902)
Agent for Applicants
C/O Vertex Pharmaceuticals Inc.
130 Waverly Street
Cambridge, MA 02139-4242
Tel: (617) 444-6731
Fax: (617) 444-6483

Amendment, filed concurrently herewith, directing the entry of the Sequence Listing into the application.

Applicants also submit herewith substitute Specification pages 2-33 in compliance with 37 C.F.R. § 1.52. The substitute specification contains no new matter.

Applicant's believe that no additional fees are due at this time however, the Commissioner is hereby authorized to charge payment of additional fees required under 37 C.F.R. § 1.16 in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



Andrea L.C. Robidoux
(Reg.No. 47,902)
Agent for Applicants
C/O Vertex Pharmaceuticals Inc.
130 Waverly Street
Cambridge, MA 02139-4242
Tel: (617) 444-6731
Fax: (617) 444-6483




04-15 03CO

Certificate Of Mailing Under 37 CFR 1.10

Express Mailing No. EU206590924US Date of Deposit April 12, 2002

I hereby certify that this document/application is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington D.C. 20231

Angela J. Billings
(type or printed name of person mailing document/applications)


(signature of person mailing document/application)

1. Transmittal Letter for Notice to File Corrected Papers
2. Notice to File Corrected Papers
3. Response to Notice to File Corrected Papers
4. Preliminary Amendment
5. Replacement Specification pages 2-33
6. Sequence Listing & Diskette
7. Verified Statement Under 37 C.F.R.
8. Copy of Executed Declaration and Power of Attorney
9. Certificate of Mailing
10. Return Receipt Postcard



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D C 20231
www.uspto.gov

10/008,277

12/03/2001

FIRST NAMED APPLICANT

Francesco Salituro

ATTORNEY DOCKET NUMBER

VPI/99-06 CON

FORMALITIES LETTER



OC000000007474615

Tina Powers

VERTEX PHARMACEUTICALS INC.

130 Waverly Street

Cambridge, MA 02139-4242

NOTICE TO FILE CORRECTED APPLICATION PAPERS

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

- A substitute specification in compliance with 37 CFR 1.52 because:

- The specification cannot be scanned or properly stored. Page(s)
 - Papers must be legibly written either by a typewriter or mechanical printer in permanent ink or its equivalent in portrait orientation on flexible, strong, smooth, non-shiny, durable, and white paper. Application papers must be presented in a form having sufficient clarity and contrast between the paper and the writing thereon to permit the direct reproduction of readily legible copies in any number by use of photographic, electrostatic, photo-offset, and microfilming processes and electronic reproduction by use of digital imaging and optical character recognition. Pages **2-33** are not in compliance with 37 CFR 1.52(a). *The drawings filed are unacceptable because:*
Replacement page(s), together with a statement that the replacement page(s) contain no new matter, are required.

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also

provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- **For Rules Interpretation, call (703) 308-4216**
- **To Purchase PatentIn Software, call (703) 306-2600**
- **For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov**

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE